Object

This publication is protected and available only for logged users.
This publication is protected and available only for logged users.

Title: Pharmacoeconomic analysis of second-line chemotherapy in patients with lung cancer

Abstract:

The aim of the work was to compare the cost-effectiveness of different chemotherapy schemes used in the second line chemotherapy of advanced cell lung cancer. Due to a therapeutic differences in case of the non small cel lung cancer alternative chemotherapies based on pemetrexed (PEME) and erlotinib (ERLO) were compared to docetaxel (DOC) based chemotherapy, in case of small cel lung cancer two schemes were compared: topotecan (TOPO) and cyclofosphamid-doxorubicin-vincristin (CAV). Medical records were collected retrospectively at the Katowice Oncology Center in Katowice. The patients were treated with one of the analyzed regimens between 2004 and 2012. The analysis was conducted from the perspective of the hospital. Only direct medical costs were analyzed. The cost-effectiveness of NSCLC and SCLC treatment was expressed in terms of incremental cost per additional life-year gained. Survival time was measured from the moment a patient started their second-line chemotherapy. An incremental and one-way sensitivity analyses were performed. The average cost per patient was 7350,86 PLN; 42199,52 PLN; 72695,89 PLN in the DOC, PEME and ERLO group respectively. In the SCLC group the average cost per patient were 5043,29 PLN in CAV and 9742,03 in TOPO. The average survival time from diagnosis to death of NSCLC patients treated with DOC, PEME and ERLO treatment regimen was 22,24; 21,89 and 28,09 months, respectively. In the SCLC the average patient survived 16,17 and 17,18 months from diagnosis, in CAV and TOPO, respectively. Second-line treatment for NSCLC is more cost-effective with docetaxel than with other treatment regimen. High prices of erlotinib, pemetrexed and topotecan and small differences in life expectancy increased the cost effectiveness ratio and made new type of treatment less cost-effective than standard therapy. Considering the differences in the prices of medicines and different finance systems of the health care in Poland and other countries in the world it is useful to carry out the pharmacoeconomic analyses.

Place of publishing:

Kraków

Level of degree:

2 - studia doktoranckie

Degree discipline:

onkologia ; farmakologia

Degree grantor:

Uniwersytet Jagielloński w Krakowie.

Promoter:

Agnieszka Skowron

Date issued:

2017

Format:

application/pdf

Identifier:

oai:dl.cm-uj.krakow.pl:4233

Call number:

ZB-127390

ControlNumberVIRTUA:

click here to follow the link

Language:

pol

Access rights:

tylko w bibliotece

Location of original object:

Biblioteka Medyczna Uniwersytetu Jagiellońskiego- Collegium Medicum

Object collections:

Last modified:

May 24, 2021

In our library since:

Mar 20, 2018

Number of object content hits:

17

Number of object content views in PDF format

7

All available object's versions:

http://dl.cm-uj.krakow.pl:8080/publication/4234

Show description in RDF format:

RDF

Show description in OAI-PMH format:

OAI-PMH

Edition name Date
ZB-127390 May 24, 2021
×

Citation

Citation style:

This page uses 'cookies'. More information